ESMO2025

Questions discussed in this category

What are your top takeaways in Breast Cancer from ESMO 2025?

1 Answer available

Papers discussed in this category

Annals of oncology : official journal of the European Society for Medical Oncology, 2025 Oct 18

Neoadjuvant trastuzumab deruxtecan alone or followed by paclitaxel, trastuzumab, and pertuzumab for high-risk HER2-positive early breast cancer (DESTINY-Breast11): a randomised, open-label, multicentre, phase 3 trial.

The New England journal of medicine, 2025 Oct 19

Sacituzumab Govitecan in Untreated, Advanced Triple-Negative Breast Cancer.

Related Topics